AstraZeneca
-
News
REGULATORY NEWS | AstraZeneca’s Voydeya Recommended for PNH Treatment in EU
Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of care Ultomiris (ravulizumab) or Soliris (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who…
Read More » -
News
COVID-19 Update: Here’s Where We Stand Now In the Race For A Vaccine
As large parts of the world prepare for a second wave of coronavirus cases governments have pinned their hopes on the rapid development of a vaccine to provide a route…
Read More » -
News
AstraZeneca Resumes Final Stage Trials For Its Covid-19 vaccine After Initial Halt
AstraZeneca Plc and the University of Oxford have resumed the British clinical trials of its Covid-19 vaccine, after the initial suspension over concerns with a participant who fell ill. University…
Read More » -
News
AstraZeneca Puts Leading COVID-19 Vaccine Trial On Hold
The pharmaceutical company AstraZeneca halted large, late-stage global trials of its coronavirus vaccine on Tuesday, because of a serious suspected adverse reaction in a participant. It is not yet known…
Read More » -
News
AstraZeneca Starts U.S. Final-Stage Trial of Covid-19 Vaccine
AstraZeneca Plc has begun final-stage, Phase III trial of its coronavirus vaccine AZD1222 in the U.S., according to the company´s latest statement. Trial centers across the US are recruiting up to 30,000 adults aged 18 years…
Read More » -
Clinical News
Oxford vaccine: Early Trials Show Promising Results that Suggest “Double Protection” from Coronavirus
The experimental vaccine being developed by AstraZeneca and Oxford University against the new coronavirus produced an immune response in early-stage clinical trials, data showed on Monday, preserving hopes it could…
Read More »